Fennec Pharmaceuticals Inc. (FENC)
$
7.99
+0.44 (5.51%)
Key metrics
Financial statements
Free cash flow per share
-0.2863
Market cap
209.7 Million
Price to sales ratio
5.4048
Debt to equity
0
Current ratio
4.6932
Income quality
1.1507
Average inventory
2.3 Million
ROE
2.0523
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company, focusing on innovative solutions for unmet medical needs. The weighted average number of diluted shares outstanding is 27,294,000.00 reflecting potential dilution effects on shareholder value. The company's operating expenses amount to $41,786,000.00 encompassing various operational costs incurred in its pursuit of advancing clinical candidates. The gross profit ratio is 0.93 which illustrates the efficiency of the company’s production and sales operations. In its financial disclosures, Fennec Pharmaceuticals reported depreciation and amortization expenses of $800,000.00 reflecting the wear and tear of its assets. Furthermore, the company reported an income before tax of -$71,000.00 showcasing its pre-tax profitability and underlying operational strength. With its clinical stage product candidate, PEDMARK, a formulation of sodium thiosulfate aimed at preventing platinum-induced ototoxicity in pediatric cancer patients, Fennec is committed to improving treatment outcomes in vulnerable populations. As a small-cap player with a market capitalization of $220,122,223.00 Fennec Pharmaceuticals is well positioned in the biopharmaceutical sector, contributing significantly to the overall market landscape. The stock is affordable at $8.67 making it suitable for budget-conscious investors looking for opportunities in emerging companies. However, the stock has a low average trading volume of 136,286.40 indicating lower market activity which might affect liquidity. As it belongs to the Healthcare sector, Fennec Pharmaceuticals is driving innovation and growth, establishing itself as a key player in the Biotechnology industry, shaping the future of therapeutic solutions. Investors who focus on this sector may find valuable prospects as the company navigates its clinical development and market strategies.
Is Fennec Pharmaceuticals Inc. (FENC) a good investment?
Investing in Fennec Pharmaceuticals Inc. (FENC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Fennec Pharmaceuticals Inc. (FENC)'s stock forecast?
Analysts predict Fennec Pharmaceuticals Inc. stock to fluctuate between $4.68 (low) and $9.92 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Fennec Pharmaceuticals Inc.'s market capitalization?
As of 2025-12-15, Fennec Pharmaceuticals Inc.'s market cap is $220,122,223, based on 27,549,715 outstanding shares.
How does Fennec Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Fennec Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Fennec Pharmaceuticals Inc. (FENC) stock?
To buy Fennec Pharmaceuticals Inc. (FENC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FENC. Place an order (Market, Limit, etc.).
What is the best time to invest in Fennec Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Fennec Pharmaceuticals Inc. stock ever split?
Fennec Pharmaceuticals Inc.'s last stock split was 1:3 on 2014-09-09.
How did Fennec Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $47,538,000 | EPS: -$0.02 | Growth: -97.33%.
Where can I find Fennec Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.fennecpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Fennec Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Fennec Pharmaceuticals Inc. stock?
All-time high: $11.92 (2023-12-28) | All-time low: $3.82 (2021-12-01).
What are the key trends affecting Fennec Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters' option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec's total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) are approximately $40,250,000.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to the Company entering into subscription agreements with investors in the offering, if any, and certain customary closing conditions including, but not limited to, the receipt of all necessary approvals, including approval from the Toronto Stock Exchange (“TSX”).
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 700,000 common shares on the same terms and conditions. Fennec anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) will be approximately $35,000,000, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on November 17, 2025, subject to customary closing conditions.
zacks.com
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.21 per share a year ago.
zacks.com
Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.
seekingalpha.com
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
globenewswire.com
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK ® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 with Evaluation of Both Registration and Partnering or Licensing Expected Thereafter ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.
globenewswire.com
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
zacks.com
Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
See all news
